Overview of the main outcomes in breast-cancer prevention trials

J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, S. Ashley, P. Boyle

Research output: Contribution to journalArticle

Abstract

Background: Early findings on the use of tamoxifen or raloxifene as prophylaxis against breast cancer have been mixed; we update available data and overview the combined results. Methods: All five randomised prevention trials comparing tamoxifen or raloxifene with placebo were included. Relevant data on contralateral breast tumours and side-effects were included from an overview of adjuvant trials of tamoxifen versus control. Findings: The tamoxifen prevention trials showed a 38% (95% Cl 28-46; p

Original languageEnglish
Pages (from-to)296-300
Number of pages5
JournalLancet
Volume361
Issue number9354
DOIs
Publication statusPublished - Jan 25 2003

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Overview of the main outcomes in breast-cancer prevention trials'. Together they form a unique fingerprint.

  • Cite this

    Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet, 361(9354), 296-300. https://doi.org/10.1016/S0140-6736(03)12342-2